Guiding discoveries from validation to value.

We are a sought-after partner to innovators worldwide, who come to Nextech for our rigorous approach to scientific validation and our hands-on support for successful company development. We help our portfolio through critical moments of scientific and clinical validation, where we can have the greatest impact for patients and investors.

scroll to view our portfolio

“Nextech had the depth in oncology to quickly understand our science and how effective our targeted therapies could be. Equally important, they understand how to build great companies and are a valuable, level-headed sounding board as we build our team and craft a financial strategy aligned to our plan.”

Athena Countouriotis, MD
CEO & President
Turning Point Therapeutics

Turning Point Therapeutics

“The entire Nextech team added tremendous value to our efforts as a hand-on investor: with rigorous ongoing assessment of our discovery and development programs; refinement of our business strategy; and deep connections in the Biotech/Pharm industry.”

John Josey
CEO & President
Peloton

Peloton

“Nextech offers a critical eye, both discerning and impactful, to our protein degradation approach, clinical development and partnering opportunities, and has done so since they began visiting us in New Haven years before investing.  Their depth of knowledge and collaborative approach make Nextech an important partner for us.”

John G. Houston, Ph.D.
President and CEO
Arvinas, Inc.

Arvinas, Inc.

“The team at Nextech Invest brings a passion for oncology, science and patients that makes them a terrific partner.  Blueprint Medicines has been fortunate to benefit from the early financial support and the ongoing strategic advice of the Nextech team.”

Jeff Albers
CEO & President
Blueprint Medicines

Blueprint Medicines

“The Nextech team has a deep scientific understanding of the science, a broad and reputable network with support from best-in-class Scientific Partners, and a strong emotional connection to the needs of cancer patients.”

Diego Miralles
CEO
Vividion Therapeutics

Vividion Therapeutics